Swiss National Bank Buys 3,000 Shares of Castle Biosciences, Inc. $CSTL

Swiss National Bank lifted its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 5.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,300 shares of the company’s stock after buying an additional 3,000 shares during the quarter. Swiss National Bank owned about 0.19% of Castle Biosciences worth $1,087,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Harbour Investments Inc. bought a new stake in Castle Biosciences in the first quarter valued at approximately $50,000. CWM LLC increased its stake in Castle Biosciences by 835.0% in the first quarter. CWM LLC now owns 4,142 shares of the company’s stock valued at $83,000 after purchasing an additional 3,699 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Castle Biosciences by 1,865.8% in the first quarter. GAMMA Investing LLC now owns 4,364 shares of the company’s stock valued at $87,000 after buying an additional 4,142 shares during the period. Teacher Retirement System of Texas boosted its holdings in shares of Castle Biosciences by 9.6% in the first quarter. Teacher Retirement System of Texas now owns 10,383 shares of the company’s stock valued at $208,000 after buying an additional 908 shares during the period. Finally, ProShare Advisors LLC acquired a new position in Castle Biosciences during the fourth quarter worth $230,000. Institutional investors own 92.60% of the company’s stock.

Castle Biosciences Stock Performance

NASDAQ CSTL opened at $20.57 on Tuesday. The company has a current ratio of 6.85, a quick ratio of 6.69 and a debt-to-equity ratio of 0.02. The company has a market cap of $596.69 million, a P/E ratio of -58.77 and a beta of 1.09. The company has a fifty day simple moving average of $18.77 and a 200 day simple moving average of $19.64. Castle Biosciences, Inc. has a 12-month low of $14.59 and a 12-month high of $35.84.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings data on Monday, August 4th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.66. The firm had revenue of $86.18 million for the quarter, compared to the consensus estimate of $71.53 million. Castle Biosciences had a negative net margin of 2.73% and a positive return on equity of 2.37%. Castle Biosciences has set its FY 2025 guidance at EPS. Sell-side analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on CSTL shares. Canaccord Genuity Group reduced their target price on shares of Castle Biosciences from $42.00 to $37.00 and set a “buy” rating for the company in a report on Tuesday, May 6th. Lake Street Capital lowered their price target on shares of Castle Biosciences from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, May 6th. Wall Street Zen upgraded shares of Castle Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 10th. Finally, Scotiabank reduced their price target on shares of Castle Biosciences from $44.00 to $40.00 and set a “sector outperform” rating on the stock in a research note on Wednesday, May 21st. Eight research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $37.00.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.